Forest And Cypress Announce Submission Of New Drug Application For Milnacipran For The Treatment Of Fibromyalgia Syndrome

Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced that they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for milnacipran, a unique dual-reuptake inhibitor being developed for the treatment of fibromyalgia syndrome (FMS). [click link for full article]

More: continued here

Filed under: Pain / Anesthetics on January 2nd, 2008